Newsroom

Sera Prognostics announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market.

Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics

Sera Prognostics announced that as a result of the annual Rusell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes

Sera Prognostics announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes

Sera Prognostics announced financial results for the first quarter of 2024 ended March 31, 2024.

Sera Prognostics announced financial results for the fourth quarter and full year ended December 31, 2023.

Sera Prognostics announced that it will report fourth quarter and full year 2023 financial results on Wednesday, March 20

Sera Prognostics announced that the company will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024 at 2:50 p.m. ET. 

Sera Prognostics today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal PRIME study recommended stopping enrollment due to efficacy

Sera Prognostics announced that the company will present at the upcoming 35th Annual Piper Sandler Healthcare Conference to be held November 28-30, 2023 in New York City